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Nucleophosmin (B23)Host factors are involved in Hepatitis B virus (HBV) genome replication and capsid formation during
the viral life cycle. A host factor, nucleophosmin (B23), was found to bind to HBV core protein
dimers, but its functional role has not been studied. This interaction promoted HBV capsid assembly
and decreased the degree of capsid dissociation when subjected to denaturant treatments in vitro.
In addition, inhibition of B23 reduced intracellular capsid formation resulting in a decrease of HBV
production in HepG2.2.15 cells. These results provide important evidence that B23 acts on core cap-
sid assembly via its interaction with HBV core dimers.
Structured summary of protein interactions:
B23 and Cp149 colocalize by cosedimentation through density gradient (View interaction)
Cp149 physically interacts with B23 by anti bait coimmunoprecipitation (1, 2)
B23 and B23 bind by blue native page (View interaction)
Cp149 and B23 bind by cosedimentation through density gradient (View interaction)
B23 binds to Cp149 by anti bait coimmunoprecipitation (1, 2, 3, 4)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction (amino acids 150–183) nucleic acid-binding domain [6]. The C-ter-Hepatitis B virus (HBV), a member of Hepadnaviridae family, is a
human pathogen that causes acute and chronic hepatitis [1].
Among 2 billion people who have been infected by HBV, around
240 million people remain chronically infected [2]. Chronic infec-
tion with HBV is closely related to the development of liver cirrho-
sis and hepatocellular carcinoma [3].
HBV contains a 3.2 kb partially double-stranded DNA genome
which has four open reading frames (ORFs) encoding four viral pro-
teins: core protein (Cp), surface protein (S), polymerase (P), and X
protein (X) [4]. Replication of HBV genome involves reverse tran-
scription of an RNA intermediate called pregenomic RNA (pgRNA)
[4]. The pgRNA and HBV polymerase along with associated host
factors are encapsidated by core protein [5]. The pgRNA-containing
T = 4 icosahedral nucleocapsid [5] plays an essential role in the
virus life cycle, given that reverse transcription regenerates the
virus genome after encapsidation [4]. The HBV core protein, which
is 183 amino acids long, consists of two domains, an N-terminal
(amino acids 1–149) core assembly domain and a C-terminalminal truncated form of core protein, Core protein 149 (Cp149;
truncated at amino acid 149), includes the assembly domain that
spontaneously forms a capsid in vitro and in vivo [7]. Given that
core assembly can occur without C-terminal nucleic acid-binding
domain, Cp149 has been generally used for the research of moni-
toring capsid assembly since 1990 [7–9]. Cp149 has advantages be-
cause of not only the efﬁciency with which it can be expressed and
puriﬁed but also the structural similarity with full length core pro-
tein [10]. During capsid formation, several host factors have been
identiﬁed to interact with core protein [11,12].
Nucleophosmin (B23), which comprises an N-terminal oligo-
merization domain, a central acidic domain, and a C-terminal
RNA binding domain, regulates ribosome biogenesis and transport,
tumor suppression, and nucleic acid binding [13]. B23 also acts as a
chaperone insofar as it suppresses the misfolding of target proteins
and protects them against denaturation [13]. Within cells, B23 ex-
ists mostly as an oligomer and its oligomeric status might be crit-
ical for chaperone activity [13]. Especially, B23 interacts with viral
proteins from several different viruses, and promotes the replica-
tion cycles of viruses. Interaction between B23 and adenoviral pro-
tein V promotes virus assembly during virion maturation [14]. B23
also form a complex with Hepatitis Delta virus (HDV) antigens to
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Human Immunodeﬁciency virus (HIV) protein Tat to ensure the
proper nucleolar localization of Tat [16]. These interactions link
B23 with the viral life cycle as a chaperone protein is advantageous
for its virus replication cycle.
In our previous study, we have reported the interaction be-
tween B23 and HBV core protein in vitro and in vivo [11], but
the functional role of its interaction in the HBV life cycle remains
to be elucidated. On the basis of these facts, we hypothesized that
B23 may affect HBV life cycle by acting as a molecular chaperone.
In the present study, we aimed to determine the functional role of
B23 in HBV replication. Here we report both in vitro and in vivo
evidence that B23 increases capsid formation by facilitating the
assembly reaction through its interaction with core protein dimers.2. Materials and methods (see also Supplementary data)
2.1. Expression and puriﬁcation of Cp149 and B23
Cp149 and Cp149 mutants were cloned directly from pET28b
vector (Novagen), and B23 and B23 mutants were cloned directly
from pET21a vector (Novagen). Constructs were transformed into
BL21(DE3)pLysS Escherichia coli (Novagen). Proteins were induced
by 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and were
incubated for an additional 4 h at 37 C. Cp149 dimers and its mu-
tants were puriﬁed as previously described [10] and stock solution
of proteins [1 mg/ml in 100 mM glycine buffer (pH9.5) containing
10% glycerol] were stored at70 C. The yields of proteinswere var-
ied between 10 and 20 mg per g weight of starting cells. B23 and its
mutants were puriﬁed as previously described [11] and stock solu-
tion of proteins [1 mg/ml in 20 mMTris–HCl buffer (pH7.5) contain-
ing 10% glycerol] were stored at70 C. The yields of proteins were
varied between 7 and 13 mg per g weight of starting cells.
2.2. Co-immunoprecipitation (co-IP), Cp149 assembly analysis and
sucrose density gradient analysis
Cp149-WT and Cp149 point mutants W125L, W125K, and
W125E (each 20 lM) were mixed with B23-WT (20 lM), and
Cp149 dimers (20 lM) were mixed with B23-WT and B23 point
mutants D286A, D286E and D286K (each 20 lM). The mixtures
were incubated at 30 C for 1 h in assembly buffer [12] and were
co-immunoprecipitated using anti-HBV core (Santa Cruz Biotech-
nology) and anti-B23 antibodies (Abcam). The immunoprecipit-
ants were analyzed by 15% SDS–PAGE, followed by immunoblot
analysis with antibodies described above. Sucrose density gradi-
ent analysis was performed by ultracentrifugation as described
previously [12], and fractions 1–10 were resolved by 15%
SDS–PAGE and immunoblot analysis was performed using
antibodies above.
2.3. Cell culture, inhibitors treatment in HepG2.2.15 cells and detection
of the HBV intracellular capsid
The human hepatoma HBV genomes expressing cell line,
HepG2.2.15, was cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Welgene) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen) at 37 C in 5% CO2. HepG2.2.15 cells were treated
with 1 lM NSC348884, B23 inhibitor, (Santa Cruz Biotechnology)
or 4 lM geldanamycin (GA), Hsp90 inhibitor, (A.G. Scientiﬁc Inc.)
or 85 lM lamivudine (Sigma) for 48 h as described previously
[Shim, Qi]. HepG2.2.15 cells were transfected with siRNA-B23
(Santa Cruz) at 150 nM by using Fugene 6.0 transfection reagent
(Roche) according to manufacturer’s protocol. After 48 h of chem-
ical treatment, cells were lysed in lysis buffer (50 mM Tris–HCl,150 mM NaCl, 5 mM EDTA, and 0.5% NP-40) as described
previously [12], and intracellular capsids from HepG2.2.15 cells
were detected as described previously [21].
2.4. Quantiﬁcation of HBV DNA and RNA by real-time quantitative PCR
After 48 h of treatment, intracellular and extracellular HBV DNA
was extracted by phenol–chloroform extraction method as de-
scribed previously [shim, park]. Total RNA was isolated from
HepG2.2.15 cells by using RiboZol RNA extraction reagent (Amre-
sco) according to the manufacturer’s instructions and was treated
with DNase I for 1 h at 37 C to eliminate residual DNA. Reverse
transcription of 1 lg total RNA was performed by using AMV re-
verse transcriptase (Promega). The resulting cDNA and HBV DNA
were measured by real-time PCR using a SYBR-Green reaction mix-
ture (Qiagen) as previously described [shim] with following prim-
ers in Supplementary Table 3.
2.5. Statistical analysis
Data, represented as bar graphs, are expressed as the mean and
standard deviation of 3 independent experiments. Statistical anal-
yses were performed using Student’s t test.3. Results
3.1. Cp149 W125 residue interacts with B23 D286 residue
To determine the binding site of HBV core protein and B23,
interaction simulation was done by docking prediction from the
obtained protein structures (Fig. 1A). We expected that 125 trypto-
phan residue (W125) of core protein and 286 aspartic acid residue
(D286) of B23 played critical roles on its interaction. In order to
conﬁrm the in sillico predictions, point mutants of Cp149 W125
residues and B23 D286 residues were generated by site-directed
mutagenesis. Cp149 and B23 mutants were investigated on their
ability to from capsid and oligomers, respectively (Fig. S1). The
two independent co-immunoprecipitation analyses showed that
the binding afﬁnities of Cp149 W125 mutants with B23-WT
(Fig. 1B) and of Cp149-WT with B23 D286 mutants were lower
than the binding afﬁnity of Cp149-WT and B23-WT (Fig. 1C). Also,
sucrose density gradient analysis showed Cp149-WT and B23-WT
were sedimented together by the interaction, whereas Cp149
W125K mutant and B23 D286A mutant were not able to bind,
thereby B23 mutant located in different fraction from the capsid
(Fig. 1D). These results clearly demonstrated that W125 residue
of Cp149 and D286 residue of B23 were strongly involved in bind-
ing of the Cp149 with B23.
3.2. B23 facilitates HBV core protein assembly and increases capsid
stability
In vitro assembly of core protein with B23 was performed to
examine how B23 affects the functions of the Cp149. The capsid for-
mation of Cp149 increased in manner dependent on the concentra-
tion of B23 (Fig. 2A). In addition, capsid assembly of Cp149 mutant
C61Awas also increased inmanner dependent on the concentration
of B23 (Fig. S2). It was also conﬁrmed that B23 increased the level of
capsid formation by sucrose density gradient analysis (Fig. 2B). Bo-
vine serum albumin (BSA) was tested and used as a positive control
in this study (Fig. S3). In order to conﬁrm B23 facilitated the rate of
capsid formation, the changes in intensity of capsid were measured
after different time intervals. Capsid formation was faster in the
presence of B23 than in the presence of either BSA or B23 D286A
(Fig. 2C). The HBV stability was investigated under the dissociation
Fig. 1. Cp149 W125 residue interacts with B23 D286 residue. (A) Simulation of the interaction between Cp149 and B23. Blue corresponds to Cp149 and red corresponds to
B23. Cp149 W125 residue and B23 D286 residue are indicated by white arrow, and green lines indicate possible weak interaction sites. (B) Cp149-WT and Cp149 mutants
W125L, W125K, and W125E were mixed with B23-WT, and (C) Cp149-WT were mixed with B23-WT and B23 mutants D286A, D286E and D286K. The mixture was co-
immunoprecipitated using anti-HBV core and anti-B23 antibodies. 5% of total input was used as positive control and non-speciﬁc normal mouse IgG was used as negative
control. (D) Sucrose density gradient analysis was performed after capsid assembly reaction either with Cp149-WT and B23-WT or with Cp149 W125K and B23 D286A.
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increasing concentration of urea or Gu-HCl, capsid levels were de-
creased in the presence of BSA, whereas B23 decreased the degree
of capsid dissociation (Fig. 2D and Fig. S4). These results showed that
B23 increased capsid stability, thereby preventing the capsid disso-
ciation by denaturing agents.
3.3. B23 can facilitate core capsid assembly in an environment that
does not favor assembly
The HBV capsid formation is temperature-dependent [17], and
B23 has a molecular chaperone activity which is able to suppress
the misfolding and aggregation of target proteins at high tempera-
ture [13]. To examine whether B23 also had the chaperone activity
toward the core protein, the effect of B23 on capsid assembly was
studied in various range of temperatures. From the data, capsidformation was maximal at 37 C in the BSA group, whereas B23
promoted capsid formation over a wide range of temperatures
(Fig. 3A).
Calcium ion is necessary for the assembly and stability of capsid
in many kinds of viruses including SV40 [18]. Moreover, the
assembly of HBV core protein is inﬂuenced by the concentration
of calcium ions both in vitro and in vivo [10]. As the concentration
of calcium ions increased, the levels of core assembly was in-
creased in the presence of BSA (Fig. 3B). However, the rate of capsid
formation in the B23 group was already maximal in the absence of
calcium (Fig. 3B). This demonstrated that B23 mediated capsid
assembly independent of the concentration of calcium ions. Taken
together, B23 performed the role as a chaperone protein during
capsid assembly and promoted capsid formation under assembly
unfavored conditions such as at high temperature or at low con-
centration of calcium ions.
Fig. 2. B23 facilitates HBV core assembly. (A) Cp149 dimer (20 lM) were incubated with increasing concentration of B23 (0–20 lM) in assembly buffer at 37 C for 30 min.
Samples were separated by 0.9% native agarose gel electrophoresis, and capsid were detected by immunoblot analysis with anti-HBV core antibody. (B) Sucrose density
gradient analysis was performed after capsid assembly reaction with or without B23 (20 lM). Cp149 incubated with BSA (20 lM) was used as a control (top). Fraction 1 and 2
contained dimers and fraction 6–8 contained assembled capsid. The amount of core dimer and capsid with or without B23 were showed in the graph (bottom left). The
relative capsid intensity was shown in the graph (bottom right). (C) Capsid formations in the presence 20 lM of BSA, B23 and B23 D286A were monitored for 120 min using
immunoblot analysis. The relative capsid intensity was determined by normalization relative to the ﬁnal abundance of capsid after assembly was completed by 120 min, as
shown in the graph (right). (D) Cp149 was incubated with or without B23 in assembly buffer at 37 C for 30 min and samples were then mixed with different concentration of
urea (1–3 M). Capsid without any additive was denoted as C. ⁄P < 0.05.
854 H. Jeong et al. / FEBS Letters 588 (2014) 851–8583.4. Oligomerization of B23 is required for the increase in capsid
assembly
When B23 functions as a chaperone protein, oligomerization of
B23 is known to be an essential factor [13]. Consequently, we
assumed that oligomerization of B23 might be mandatory for its
chaperone activity toward HBV core protein. First, we used
co-immunoprecipitation analysis to examine whether oligomeri-
zation of B23 was necessary for its interaction with core protein.
Given that the B23 mutant C21F is defective in oligomerization
[19], C21F was used as a monomer in this analysis. The HBV core
dimer could interact only with B23 oligomer but not with B23
monomer (Fig. 4A). These showed that the oligomerization of
B23 was mandatory for its interaction with core protein. Consistent
with the data, C21F (a monomeric form of B23) could not promote
capsid assembly (Fig. 4B). When NSC348884, a B23 inhibitor thatdisrupts oligomer formation [20], was incubated with B23 during
capsid assembly, the level of capsid assembly decreased to the le-
vel observed in the absence of B23 (Fig. 4C). Based on these results,
B23 was able to interact with the HBV core protein and to promote
capsid assembly only when B23 existed as an oligomer.
3.5. Inhibition of B23 in the HepG2.2.15 cell line reduces HBV
replication
To analyze the role of B23 in HBV replication cycle, the extracel-
lular and intracellular HBV DNA levels were quantiﬁed after knock-
down or inhibition of B23 in the HepG2.2.15 cells. Inhibitors used
in this study showed no effect on cell viability by MTT assay
(Fig. S5). The knock-down of B23 and treatment with NSC348884
decreased the levels of extracellular and intracellular HBV DNA
by 60% (Fig. 5A), and HBV polymerase inhibitor, lamivudine
Fig. 3. B23 can facilitate core capsid assembly in environment that does not favor assembly. (A) Cp149 capsid assembly reaction with or without B23 at a wide range of
temperatures (27–47 C) were performed for 30 min. Capsid without any additive at 27 C was denoted as C and was used as a standard.(B) Cp149 capsid assembly reaction in
each reaction buffer with different concentration of Ca2+ (0–2 mM) with or without B23 was performed for 30 min. Capsid without any additive in 0 mM Ca2+ was denoted as
C and was used as a standard. ⁄P < 0.05.
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3TC together, both extracellular and intracellular HBV DNA levels
were reduced by 90% (Fig. 5A). The change of extracellular HBV
DNA levels after B23 inhibition demonstrated that B23 affected
the proliferation of HBV. Also, B23 was not able to affect the mech-
anisms of HBV virion secretion since the extracellular and the
intracellular HBV DNA titers had no differences. To understand
whether B23 affect HBV transcription, we measured the expression
level of HBV RNAs. However, expression level was not affected nei-
ther by inhibition of B23 nor treatment with 3TC (Fig. 5B). The re-
sult supported clearly that B23 were not involved in the
transcription of cccDNA into HBV RNAs.
After inhibition, the cells were lysed, and the intracellular cap-
sid levels were measured by immunoblot analysis. Since Hsp90 has
been proven to facilitate HBV capsid formation [12], HepG2.2.15
cells were treated with Hsp90 inhibitor, GA, in the presence or ab-
sence of NSC348884. The inhibition of B23 or Hsp90 reduced intra-
cellular capsid formation by 50% or 40%, respectively (Fig. 5C).
Moreover, the amount of capsid formation was synergically re-
duced by 90% after inhibition of B23 and Hsp90 (Fig. 5C), since both
Hsp90 and B23 were involved in capsid formation. However, the
level of HBV core protein synthesis was not affected by the treat-
ment of inhibitors when the expression level of the core proteinwas detected by immunoblot analysis (Fig. 5C). These results
clearly demonstrated that B23 acted on capsid formation, but not
on the translation of core protein. In summary, the inhibition of
B23 interrupted to produce viral DNA by impeding capsid assem-
bly, so that HBV polymerase could not properly function in the
HepG2.2.15 cells.
4. Discussion
During the HBV life cycle, HBV core proteins assemble to
encapsidate pregenomic RNA (pgRNA) and the polymerase
required for HBV replication [4]. Given the small size of the
HBV genome, which encodes four viral proteins, HBV depends
critically on host factors for the infection and replication [4].
Accordingly, host factors have been shown to interact with viral
components to assist several steps in HBV replication, including
priming of the HBV polymerase, promoting the interaction be-
tween polymerase and pgRNA, and encapsidating the polymerase
and pgRNA [8,21]. Several host factors are involved in capsid
formation. Protein kinase A (PKA) and protein kinase C (PKC)
phosphorylate HBV core protein, which increases capsid assem-
bly [8]. In addition, Hsp90 binds to the HBV core protein to facil-
itate not only HBV capsid assembly but also the production of
Fig. 4. Oligomerization of B23 is required for B23 mediated promotion of capsid assembly. (A) After Cp149 capsid assembly reaction each with B23-WT oligomers (left panel)
or B23 mutant C21F monomers (right panel), the mixture was co-immunoprecipitated using anti-HBV core and anti-B23 antibodies. (B) Capsid assembly reaction with
increasing concentrations of B23-WT (left panel) or B23 mutant C21F (0–20 lM) was performed. (C) After the assembly reaction with B23 along with increasing concentration
of B23 inhibitor NSC348884, capsids were detected by immunoblot analysis. ⁄P < 0.05.
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chaperone proteins, Hsp40 decreases capsid formation and
inhibits HBV replication [22].
In our result, HBV core protein interacted with B23 oligomers
(Fig 4). In living cells, nuclear-cytoplasmic shuttling of HBV core
protein is regulated by phosphorylation of serine in C-terminal do-
main [23]. In addition, B23 is moving constantly between nuclear
and cytoplasm as it contains nuclear localization signal (NLS) and
nuclear export signal (NES) sequences [13]. Therefore, we assumed
a strong possibility that interaction between core protein and B23
occur in living cells. Consistent with this hypothesis, the in vivo
interaction between B23 and core protein have been reported
[11]. This interaction facilitates HBV capsid formation in vitro
and in vivo (Figs. 2 and 5C). Based on these results, we hypothe-
sized that the binding of B23 to the HBV core protein may change
the conformations of core proteins, which increases the afﬁnity of
core–core interaction [9]. As a result, the increase in core dimerafﬁnity may assist to maintain core–core interactions within the
capsid and decrease the rate of capsid dissociation.
To understand the mechanism how B23 is involved to affect
HBV life cycle, each step of HBV life cycle was investigated. Our re-
sults conﬁrmed that the inhibition of B23 in the HepG2.2.15 cells
decreases extracellular HBV titers by preventing the formation of
HBV capsids (Fig. 5). These suggest that B23 assists in the process
of capsid assembly to enhance HBV replication. Moreover,
combined inhibition of B23 and Hsp90 decreased the HBV capsid
formation in cooperative manner (Fig. 5C). Further study is needed
to understand the mechanism of how B23 and Hsp90 cooperatively
impact capsid assembly during HBV replication cycle.
Among available HBV therapies, HBV polymerase has been a
target for inhibiting HBV replication, and HBV polymerase inhibi-
tors including lamivudine, adefovir, and entecavir have been used
to cure HBV patients [24]. However, there is a limitation of the
inhibitors due to the emergence of drug resistance [24]. Therefore,
Fig. 5. Inhibition of B23 reduces HBV replication. (A) Extracellular and intracellular HBV DNA titers were measured by qRT-PCR. (B) Intracellular total RNAs was extracted
from HepG2.2.15. After reverse transcription, the relative level of RNA expression was quantiﬁed by qRT-PCR. (C) HepG2.2.15 cells were lysed in lysis buffer and capsids, core
protein, and B23 were analyzed by immunoblot analysis. B-actin was used as a control.
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ing is the another strategy to overcome the challenge of the drug
resistance.
In conclusion, B23 is involved in HBV replication cycle as a cel-
lular chaperone via direct interaction with core protein. The ability
of B23 to facilitate HBV capsid formation in vitro and in vivo points
to its role in controlling HBV proliferation in vivo. Given that capsid
assembly is critical to complete the HBV life cycle, the mechanism
of B23 mediated viral assembly may be an important step for HBV
proliferation.
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